drugset / Trial / NCT07006805
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
Non-randomizedSequentialOpen-labelTreatment
Summary
RESET-MS: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Multiple Sclerosis
Timeline
- Start
- 2026-06
- Primary completion
- 2028-09
- Completion
- 2029-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | resecabtagene autoleucel | Cell therapy | — | Intravenous |